NEO · XBRL financial data

Neogenomics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NEO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	259	297	322	347	370	413
Gross profit	186	187	188	245	290	314
Research and development	8	22	30	27	31	37
General and administrative	144	221	243	243	260	273
Total operating expenses	200	306	346	352	382	430
Operating income (loss)	(14)	(119)	(158)	(108)	(92)	(116)
Interest income	—	—	6	17	18	9
Interest expense	7	5	2	7	7	4
Other income (expense)	12	(0)	(0)	1	(0)	0
Income tax expense (benefit)	(18)	(7)	(15)	(9)	(2)	(2)
Net income (loss)	4	(8)	(144)	(88)	(79)	(108)
Weighted average shares, basic millions of shares	109	120	124	126	127	128
Weighted average shares, diluted millions of shares	112	120	124	126	127	128

Fiscal years (NEO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	229	317	263	342	367	160
Marketable securities	68	199	—	—	—	—
Accounts receivable	107	112	120	131	151	159
Inventory	30	23	24	24	27	29
Total current assets	449	682	605	597	596	376
Property and equipment, net	86	109	102	92	94	85
Right-of-use asset	46	102	96	92	80	78
Goodwill	211	527	523	523	523	524
Total assets	988	1,870	1,740	1,681	1,638	1,360
Accounts payable	25	18	21	20	22	23
Current portion of long-term debt	0	—	—	—	201	0
Total current liabilities	73	87	90	96	301	88
Long-term debt	—	—	—	538	340	342
Lease liability, non-current	42	72	69	68	61	63
Total liabilities	294	762	742	740	736	523
Accumulated deficit	(7)	(15)	(159)	(247)	(326)	(434)
Total stockholders' equity	694	1,108	998	942	902	837
Total liabilities and equity	988	1,870	1,740	1,681	1,638	1,360
Common shares outstanding (cover page) millions of shares	117	124	127	128	128	130

Fiscal years (NEO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	4	(8)	(144)	(88)	(79)	(108)
Stock-based compensation	10	22	25	25	33	41
Net cash from operating activities	1	(27)	(66)	(2)	7	5
Purchases of property and equipment	29	64	31	29	41	27
Net cash from investing activities	(159)	(632)	1	77	13	(12)
Proceeds from issuing common stock	20	15	13	5	5	1
Net cash from financing activities	236	725	12	5	5	(200)
Net change in cash	78	—	—	—	—	—

SIC 8734 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8734 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Neogenomics	139	209	(8.9)*	129.4M	18.9 quarters	Q3 FY26 10-QSep 30, 2026
Absci	108	not reported	(28)*	171.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
Maxcyte	15	7.3	(4.7)*	103.2M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
NRC Health	3.6	38	8*	21.2M	—	Q3 FY26 10-QSep 30, 2026
OmniAb	23	4	11*	145.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.